Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 11Lung Neoplasms 5Breast Neoplasms 2Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Advanced Solid Tumors 1

Interventions

pembrolizumab 3Proton Therapy 2ribociclib 1palbociclib 1napabucasin 1fludarabine 1epacadostat 1bosutinib 1amrubicin 1alovudine 1Sunitinib 1Radiotherapy 1Radiosurgery 1Radiation 1Plicamycin 1Pemetrexed 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Erlotinib Hydrochloride 1Drug Therapy 1Cyclophosphamide 1Cisplatin 1Bevacizumab 1Albumin-Bound Paclitaxel 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thymus Neoplasms × amrubicin × Clear all
NCT01364727 2019-04-16

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Stanford University

Phase 2 Completed
33 enrolled 11 charts
Thoracic

Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡